Entities / Company
Catalyst Pharmaceuticals.
company in Coral Gables, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 30
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
Citigroup downgraded the stock rating and target price for Catalyst Pharmaceuticals on June 16, 2026.Some support1 report
-
Catalyst Pharmaceuticals filed a disclosure with the Securities and Exchange Commission on June 15, 2026.Some support1 report
-
Catalyst Pharmaceuticals, a US biopharma company, is licensed by SERB and previously settled litigation with Teva Pharmaceuticals.Some support2 reports
-
Zacks provided stock analysis and ratings for Catalyst Pharmaceuticals on July 7, 2025.Speculative2 reports
-
Catalyst Pharmaceuticals, SunOpta, and Orion Group were highlighted in a stock analysis report on July 24, 2025.Some support1 report
-
Daniel Curran was appointed to the Board of Directors of Catalyst Pharmaceuticals.Some support1 report
-
Incepta Pharmaceuticals and Catalyst Pharmaceuticals were mentioned in a recent report.Some support1 report
-
Catalyst Pharmaceuticals is based in Coral Gables, Florida.Some support3 reports
-
Lupin and Catalyst Pharmaceuticals settle patent litigation on August 26, 2025, involving FDA approval of Firdapse label expansion for pediatric patients and market generic status.Some support2 reports
-
Richard J. Daly was appointed President and CEO of Catalyst Pharmaceuticals on August 28, 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Catalyst Pharmaceuticals this week
News at the entities that move Catalyst Pharmaceuticals most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Catalyst Pharmaceuticals
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Catalyst Pharmaceuticals
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves Catalyst Pharmaceuticals
-
Morgan Stanley TransactionalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Catalyst Pharmaceuticals
-
Citigroup OperationalCitigroup provided analyst ratings and targets for Autodesk stock, which trades on Nasdaq.Moves Catalyst Pharmaceuticals
Connections
The 8 strongest of 30, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Richard J. Daly Structural
Richard J. Daly serves as the President and CEO of Catalyst Pharmaceuticals.
-
FDA Structural
The FDA provides regulatory oversight and approves drug label expansions for Catalyst Pharmaceuticals.
-
SEC Structural
Catalyst Pharmaceuticals operates under the regulatory oversight of the SEC, specifically regarding mandatory disclosure of share holdings.
-
SERB Structural
SERB functions as the licensor for Catalyst Pharmaceuticals, establishing a formal structural dependency.
-
Securities and Exchange Commission Structural
Catalyst Pharmaceuticals operates under the formal regulatory oversight and filing requirements of the SEC.
-
Morgan Stanley Transactional
Morgan Stanley purchased shares of Catalyst Pharmaceuticals.
-
Citigroup Operational
Citigroup downgraded the stock rating and target price for Catalyst Pharmaceuticals.
-
Coral Gables Shared context
Catalyst Pharmaceuticals is based in Coral Gables.
History
Events by the month they beganJuly 2026
1 eventJune 2026
10 events- Citigroup downgraded the stock rating and target price for Catalyst Pharmaceuticals on June 16, 2026.
- Catalyst Pharmaceuticals filed a disclosure with the Securities and Exchange Commission on June 15, 2026.
- Catalyst Pharmaceuticals, a US biopharma company, is licensed by SERB and previously settled litigation with Teva Pharmaceuticals.
- Zacks provided stock analysis and ratings for Catalyst Pharmaceuticals on July 7, 2025.
- Catalyst Pharmaceuticals, SunOpta, and Orion Group were highlighted in a stock analysis report on July 24, 2025.
- Daniel Curran was appointed to the Board of Directors of Catalyst Pharmaceuticals.
- Incepta Pharmaceuticals and Catalyst Pharmaceuticals were mentioned in a recent report.
- Catalyst Pharmaceuticals is based in Coral Gables, Florida.
- Lupin and Catalyst Pharmaceuticals settle patent litigation on August 26, 2025, involving FDA approval of Firdapse label expansion for pediatric patients and market generic status.
- Richard J. Daly was appointed President and CEO of Catalyst Pharmaceuticals on August 28, 2025.